title: [Molecular approaches to systemic therapy of adenoid cystic carcinoma of the head and neck area].
abstract: The adenoid cystic carcinoma (ACC) is a neurotropic salivary gland tumor with a high blood-borne metastasis tendency. The treatment of choice for localized disease consists of radical surgical resection and, depending on resection status, adjuvant radiotherapy. Due to the high recurrence rate with limited local therapeutic options and frequent occurrence of distant metastases, one is confronted inevitably with the search for an adequate systemic therapy. ACC shows little response to a variety of chemotherapeutic agents, partial or complete remissions are extremely rare. Beside classical chemotherapies, immunotherapeutics and targeted therapies with more favorable side effect profiles were tested in trials, but due to the small number of patients, a definitive statement on the effectiveness can be hardly made. This results in the need for prospective multicenter studies that allow clear recommendations for systemic therapy of the tumor. The present paper gives an overview of the sub-cellular and genetic characteristics of ACC, which represent possible targets for systemic therapies and have partly already been included in running clinical trials.
authors.affiliation: Klinik für Hals-Nasen-Ohren-Heilkunde, Kopf- und Halschirurgie, Universitätsklinikum Essen, Essen.
authors.forename: K
authors.initials: K
authors.lastname: Büchsenschütz
authors.affiliation: Klinik für Hals-, Nasen-, Ohrenheilkunde, Universitätsklinikum Ulm, Ulm.
authors.forename: J A
authors.initials: JA
authors.lastname: Veit
authors.affiliation: Klinik für Hals-, Nasen-, Ohrenheilkunde, Universitätsklinikum Ulm, Ulm.
authors.forename: P J
authors.initials: PJ
authors.lastname: Schuler
authors.affiliation: Klinik für Hals-, Nasen-, Ohrenheilkunde, Universitätsklinikum Ulm, Ulm.
authors.forename: J
authors.initials: J
authors.lastname: Thierauf
authors.affiliation: Klinik für Hals-, Nasen-, Ohrenheilkunde, Universitätsklinikum Ulm, Ulm.
authors.forename: S
authors.initials: S
authors.lastname: Laban
authors.affiliation: Klinik für Hals-Nasen-Ohren-Heilkunde, Kopf- und Halschirurgie, Universitätsklinikum Essen, Essen.
authors.forename: F
authors.initials: F
authors.lastname: Fahimi
authors.affiliation: Institut für Pathologie und Neuropatholgie, Universitätsklinikum Essen, Essen.
authors.forename: A
authors.initials: A
authors.lastname: Bankfalvi
authors.affiliation: Klinik für Hals-Nasen-Ohren-Heilkunde, Kopf- und Halschirurgie, Universitätsklinikum Essen, Essen.
authors.forename: S
authors.initials: S
authors.lastname: Lang
authors.affiliation: Klinik für Strahlentherapie, Universitätsklinikum Essen, Essen.
authors.forename: W
authors.initials: W
authors.lastname: Sauerwein
authors.affiliation: Klinik für Hals-, Nasen-, Ohrenheilkunde, Universitätsklinikum Ulm, Ulm.
authors.forename: T K
authors.initials: TK
authors.lastname: Hoffmann
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001688:Biological Products / Q000627:therapeutic use*; D003528:Carcinoma, Adenoid Cystic / Q000188:drug therapy* / Q000235:genetics / Q000473:pathology; D004252:DNA Mutational Analysis; D005819:Genetic Markers / Q000235:genetics*; D015316:Genetic Therapy / Q000379:methods; D006801:Humans; D007155:Immunologic Factors / Q000627:therapeutic use; D007167:Immunotherapy; D058990:Molecular Targeted Therapy; D010039:Otorhinolaryngologic Neoplasms / Q000628:therapy*; D057285:Precision Medicine; D015398:Signal Transduction / Q000187:drug effects
chemical_list: D000970:Antineoplastic Agents; D001688:Biological Products; D005819:Genetic Markers; D007155:Immunologic Factors